Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Dealmaking Landscape According to Sanofi

And Advice For Potential Partners

Executive Summary

Monika Vnuk, head of Sanofi’s business development, tells Scrip that the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Lilly’s latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.

Deal Watch: Tourmaline Will Pursue Its Thyroid Eye Disease Ambitions Following Merger With Talaris

Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.

AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

When patients should receive the RSV prevention treatment was the subject of much debate even as the Antimicrobial Drugs Advisory Committee voted nearly unanimously that it should be approved for infants and neonates.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel